EyePoint, Inc. (EYPT) News
Follow EyePoint, Inc. (EYPT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 30 public stories across 18 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
EyePoint Q3 Earnings Preview: Revenue Estimate Reported
EyePoint is scheduled to report Q3 results on November 04. Revenue is estimated at 231.15 thousand USD and EPS at (0.93) USD; the release time is not specified.
EQUITY | Oct 28, 2026, 11:06 AM UTC
M
EYPT, CRWV and EOSE Hit Fresh 52-Week Lows
EyePoint Pharmaceuticals, CoreWeave and Eos Energy Enterprises hit fresh 52-week lows Monday. A failed drug trial, debt refinancing concerns and weaker full-year revenue expectations weighed on the stocks; EyePoint fell
EQUITY | Oct 20, 2026, 02:40 AM UTC
M
Five Stocks Draw Attention After Earnings, Trial Results and Merck Deal
Cleveland-Cliffs reported third-quarter adjusted EPS of 28 cents and projected fourth-quarter adjusted EBITDA of approximately $715 million. Disc Medicine reported positive Phase 3 results, Merck agreed to acquire Silenc
EQUITY | Oct 20, 2026, 01:04 AM UTC
M
EyePoint Reports Second Late-Stage Duravyu Study Failure
EyePoint reported a second late-stage study failure for its proposed Duravyu treatment for wet age-related macular degeneration. Its shares fell sharply on Monday.
EQUITY | Oct 19, 2026, 01:45 PM UTC
H
EyePoint to Cut 53% of Workforce After Trial Failure
EyePoint said it would stop studies of its experimental age-related vision disease drug after a second late-stage trial failed. Its shares fell more than 75% in premarket trading.
EQUITY | Oct 19, 2026, 12:19 PM UTC
M
EyePoint to Cut Workforce 53% After Experimental Drug Fails Trial
EyePoint said it would cut about 53% of its workforce and stop studies of its experimental drug for an age-related vision disease after the drug failed a second late-stage trial.
EQUITY | Oct 19, 2026, 11:36 AM UTC
M
EyePoint reports topline results from second pivotal Phase 3 DURAVYU trial
EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU in wet AMD.
EQUITY | Oct 19, 2026, 11:24 AM UTC
L
EyePoint announces strategic prioritization
EQUITY | Oct 19, 2026, 11:15 AM UTC
L
EYPT - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EYPT - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 11:00 AM UTC
L
EYPT: Strong secondary endpoints and safety drive optimism ahead of the pivotal LUCIA trial
Recent phase III data showed strong safety and reduced treatment burden for wet AMD, despite missing the primary endpoint due to unusual control arm results. The upcoming LUCIA trial will address these findings, with com
NEWS | Sep 15, 2026, 12:26 PM UTC
L
EYPT: Strong secondary outcomes and safety drive optimism ahead of pivotal LUCIA trial and DME expansion
Recent phase III data showed strong secondary outcomes and safety, despite missing the primary endpoint due to unusual control arm results. The upcoming LUCIA trial, with improved analysis, is expected to be pivotal for
NEWS | Sep 15, 2026, 11:53 AM UTC
L
EYPT LUGANO trial reports strong secondary results and safety
EYPT said its LUGANO trial produced strong secondary outcomes showing reduced treatment burden and good safety. It also said the trial missed the primary endpoint due to an unusual control arm result.
EARNINGS | Sep 10, 2026, 03:10 PM UTC
L
EyePoint posts updated presentation on LUGANO Phase 3 topline results
The investor presentation highlights LUGANO Phase 3 DURAVYU topline results. It also says a wet AMD NDA filing is targeted for H1 2027.
EQUITY | Sep 10, 2026, 11:13 AM UTC
L
EYPT optimism rises as LUCIA trial secondary endpoints look strong
DURAVYU’s phase III LUGANO wet AMD trial missed its primary endpoint on randomization imbalance, but strong secondary endpoints, safety, and reduced injection burden support confidence for upcoming LUCIA results.
EQUITY | Sep 09, 2026, 01:28 PM UTC
L
TD Cowen cuts EyePoint to Hold, trims price target to $4
TD Cowen downgraded EyePoint to Hold from Buy and cut its price target to $4.00 per share from $20.00, according to Benzinga/TradingView News.
EQUITY | Sep 02, 2026, 01:31 PM UTC
L
EyePoint to participate in upcoming investor conferences, scientific meeting
EyePoint, Inc. (NASDAQ:EYPT) announced it will participate in upcoming investor conferences and a scientific meeting.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
EyePoint announces participation at upcoming investor conferences
EyePoint (EYPT) says it will participate in upcoming investor conferences and a scientific meeting.
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
EQUITY | Aug 28, 2026, 11:10 PM UTC
L
Downgrades hit AMRC, ANF, ATHM, EYPT, JBLU, KRG, METC, NCLH, TIGO
Several brokers lower or reiterate cautious ratings on AMRC, ANF, ATHM, EYPT, JBLU, KRG, METC, NCLH and TIGO, with no catalyst supplied in the feed.
EQUITY | Aug 18, 2026, 10:44 AM UTC
L
NY Empire State Manufacturing Index Rises to 20.6 in August
The New York Fed's Empire State Manufacturing Index surged to 20.6 in August from 15.6 in the prior month, topping market estimates of 11.
EARNINGS | Aug 17, 2026, 04:04 PM UTC
L
Empire State Manufacturing Index jumps to 20.6 in August
The New York Fed’s Empire State Manufacturing Index rises to 20.6 in August from 15.6 in the prior month, exceeding market estimates of 11, as U.S. stocks trade mixed.
EARNINGS | Aug 17, 2026, 01:39 PM UTC
M
EyePoint reports topline data from LUGANO Phase 3 DURAVYU 2.7mg trial
EyePoint (EYPT) announces topline data from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU™ 2.7mg in wet AMD, with no additional figures provided.
EQUITY | Aug 17, 2026, 11:00 AM UTC
M
EyePoint grants inducement awards under Nasdaq Rule 5635(c)(4)
EyePoint Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) for EYPT.
REGULATION | Aug 14, 2026, 08:32 PM UTC
L
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EYPT - EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
EARNINGS | Aug 05, 2026, 11:01 AM UTC
H
EyePoint Completes Enrollment
EyePoint completes phase 3 trials
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
EYPT Eyepoint - enters settlement agreement with DOJ, oig-hhs, and dha on July 17, 2026 - SEC filing
REGULATION | Jul 17, 2026, 08:07 PM UTC
L
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EYPT U.S. Department of Justice - Eyepoint Pharmaceuticals to Pay $4.6M to Resolve False Claims Act Allegations
EQUITY | Jul 17, 2026, 02:35 PM UTC
L
EYPT Initiated Buy and $40 PT @ Stifel
EYPT Initiated Buy and $40 PT @ Stifel
EQUITY | Jul 16, 2026, 11:10 AM UTC
L
EYPT Initiate with a Buy, $40 PT @ Stifel
EYPT Initiate with a Buy, $40 PT @ Stifel
EQUITY | Jul 15, 2026, 08:08 PM UTC
L
Chardan Capital Maintains Buy on EyePoint, Raises Price Target to $65
Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ: EYPT ) with a Buy and raises the price target from $29 to $65.
EQUITY | Jul 01, 2026, 12:52 PM UTC